Strengthening Early-Stage AML Drug Discovery and Targeted Protein Degradation Capabilities Amgen has announced an agreement to acquire Dark Blue Therapeutics for up to $840 million, reinforcing its strategy to accelerate research and development in acute myeloid leukemia (AML). The transaction includes an upfront payment and development-based milestone payments, subject to customary closing conditions. The acquisition […]
Novo Nordisk has received approval from the U.S. Food and Drug Administration (FDA) for Wegovy®, an oral GLP-1–based therapy indicated for chronic weight management in adults with obesity or overweight with weight-related comorbidities. The decision marks the first FDA approval of an oral GLP-1 receptor agonist for obesity, introducing an alternative to injectable formulations that […]
BioMarin Pharmaceutical has announced that it will acquire Amicus Therapeutics, a company with strong expertise in rare diseases, in an all-cash transaction valued at approximately $4.8 billion.Through this acquisition, BioMarin will add approved therapies for Fabry disease and Pompe disease, significantly expanding its portfolio in the rare disease space. The transaction has attracted attention as […]
Pfizer has officially taken the lead, securing biotech innovator Metsera in a $10 billion agreement that reshapes the competitive landscape for obesity and metabolic therapies. After a week of heavy negotiations, the deal leaves Novo Nordisk on the sidelines and marks Pfizer’s biggest play in the space in years. What’s driving this acquisition A total […]
Takeda Pharmaceutical has entered into a major global collaboration with China’s Innovent Biologics, valued at up to $11.4 billion, to co-develop and commercialise next-generation cancer therapies worldwide, including in the United States. The partnership will focus on immuno-oncology and antibody-drug conjugate (ADC) treatments, led by Innovent’s key investigational assets IBI363 and IBI343, targeting solid tumours […]
Roche has received U.S. FDA approval for Gazyva®/Gazyvaro® (obinutuzumab) for the treatment of adults with active lupus nephritis, used in combination with standard therapy. This approval marks a significant step forward in the management of this complex autoimmune disease, offering patients a new therapeutic option with a shorter 90-minute infusion time. Why This Milestone Matters […]